Drug Detail

Information about Imatinib + BGJ398

Generic Name
IND	Imatinib + BGJ398
Brand Name (US)
Manufacturer	Novartis
Drug Type
Delivery	Oral
Approval Status
Indications
Overall Strategy	KIT Protein Based + Oncogenic Signal Path Based
Strategy	Block KIT & Block FGFR
Drug Category	KIT and FGFR inhiitor

Links
Trials of this drug
	BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Trial results
	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.